Yea Jin Kaeser-Woo

Wednesday 3rd June 2026

Panel Discussion: How the Industry is Leveraging Spatial Omics for ALS Target Discovery & Biomarkers?

8:30 am

How is spatial omics transforming our understanding of ALS pathology compared with traditional bulk tissue or single-cell approaches?
Which emerging ALS targets or molecular pathways have been most compellingly revealed through spatial transcriptomics, proteomics, or multi-omic integration?
How can spatial omics data be translated into actionable biomarkers for clinical trials, including patient stratification, early detection, or monitoring therapeutic response?
What are the key technical, analytical, and interpretational challenges in applying spatial omics to human ALS tissue, and how are industry and academia addressing these?
How do collaborative approaches between pharma, academic centers, and genome institutes accelerate the path from spatial omics discovery to drug development?
Looking forward, what role will AI and machine learning play in extracting meaningful insights from complex spatial omics datasets in ALS?

Wednesday 3rd June 2026

Advancing Nucleic Acid Therapies for ALS: Delivery Innovations, Multiomic Insights, & Next-Generation Target Discovery

1:00 pm

Learnings from full-cycle oligonucleotide development in ALS, spanning target validation, lead identification, and clinical candidate nomination
Delivery innovations and nucleic-acid–based strategies that may improve therapeutic reach and durability in neurodegenerative disease
How integrated data science, including bioinformatics, computational biology, and biomarker discovery, is shaping next-generation ALS programs
The role of multiomic and spatial biology platforms in enabling precision medicine approaches for ALS and other neurodegenerative disorders